Samsung Biologics Amasses Nearly 98% Stake in PolyPeptide Group

02:00 AM EST, 11/02/2026 (MT Newswires) -- PolyPeptide Group (PPGN.SW) suitor Samsung Biologics secured ownership of 32,458,892 shares, or 97.99% of the company's total issued share capital and voting rights, at the close of the extended acceptance period for the takeover offer. The Swiss peptide contract development and manufacturing organization said Monday that the provisional end result showed that 32,350,302 shares, or 97.98% of all targeted shares, have been tendered for the acceptance of the proposal as of the Oct. 30 closing. The offeror is planning a squeeze-out process for the shares not yet tendered for the proposal. The South Korea-listed Samsung Biologics made the proposal through Samsung Peptide. Completion is expected near the end of 2026 or in the first quarter of 2027, subject to other preceding conditions, including regulatory approvals. After settlement, Samsung Biologics is planning to initiate the delisting of PolyPeptide.